Pfizer CEO is again new and positive.

25.09.2022

Number of this text: 1016, reading time for about 2 minutes

Guide: The 60 -year -old Barra was first diagnosed with a new crown in mid -August. Earlier, he had inoculated the four -dose Pfizer vaccine and took Paxlovid, Pfizer's small molecule antiviral drug.

Author | First Financial Money Children's Heart

Pfizer CEO Albert Bourla said on social media on September 24 that his new crown test was positive again. This was less than a half month after his last new crown.

Barra said he felt good and had no symptoms. According to the Guide of the US Disease Control and Prevention Center (CDC), the new crown vaccine can be vaccinated after three months of infection in the new crown. Therefore, Bulla said that he has not yet vaccinated the updated version of the second -price vaccine against the Omikon BA.5 mutant.

"Although we have achieved very great achievements, the helpless virus has always existed." Bulla said.

Bulla, 60, was diagnosed with a new crown for the first time in mid -August. Earlier, he had inoculated the four -dose Pfizer vaccine and took Paxlovid, Pfizer's small molecule antiviral drug.

In the past two months, US President Biden and White House Chief Medical Officer Anthony Fauci have all appeared new crown testing again. In this regard, the US CDC has made it clear that the recurrence of the new crown symptoms may be a way for some people to infect this virus, but the data of CDC shows that the proportion of patients who are infected are quite low.

In this regard, a virus expert told the First Financial reporter: "It is generally believed that the possibility of repeated infection of the same virus variable strain within three months, because the infection will produce immunity within a certain period of time, so either interval either interval In a very short time, some people with low immunity (such as the elderly) have not cleared the clean virus in the body and rebounded, causing the detection to be positive again. I think the probability of the latter is greater from the case of Pfizer CEO, but this still needs to be concluded through the virus sample gene sequencing. "

This fall, the United States will begin to strengthen the second price of Pfizer's secondary price against Omikon BA.5. According to the latest data from the United States, BA.5 currently accounts for about 85%of the number of new infections in the United States. However, the new subtypes including Omikon BA.4.6 have been rapidly spread in the United States, and there have been many studies that BA.4.6 can further escape the immune protection generated by BA.5.

Last month, scientists confirmed a new type of Omikon subtype BA.2.75.2. A few days ago, researchers, including Peking University Xie Xiaoliang's team, published a pre -printing study saying that BA.2.75.2's ability to escape immunity is better than any current Omikon subtype.

In response to the continuous mutant virus, whether it is still necessary to repeatedly vaccinate the vaccine to obtain immunity, the academician of the Chinese Academy of Sciences Gao Fu said to the first financial reporter in a "Mozi Salon" science activity held on September 24: "At present Research still supports us to wake up immune memory through repeated vaccination, that is to say, we are likely to need to vaccinate the fourth, fifth needle, and even sixth needles to strengthen the vaccine. "He told the First Financial reporter," According to the current virus, we With the cognition of vaccine immunity, the inoculation interval of reinforcement agents is generally half a year. "

Bleak

- END -